Evidence map›Paper›PMID 38910824›Full record

ArticleProceedings (Baylor University. Medical Center)2024

Immunotherapy-induced colitis in metastatic colorectal cancer: a systematic review and meta-analysis.

Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, Diego Olavarria Bernal, Hector Garcia Pleitez, Lukman Tijani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sakditad SaowapaDepartment of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.ORCID https://orcid.org/0000-0002-4978-8674
Natchaya PolpichaiDepartment of Internal Medicine, Weiss Memorial Hospital, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-3162-8912
Pharit SiladechDepartment of Internal Medicine, Mahidol University, Bangkok, Thailand.
Chalothorn WannaphutDepartment of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
Manasawee TanariyakulDepartment of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.ORCID https://orcid.org/0009-0007-1191-8780
Phuuwadith WattanachayakulDepartment of Internal Medicine, Einstein Medical Center, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-0086-5269
Diego Olavarria BernalDepartment of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Hector Garcia PleitezDepartment of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Lukman TijaniHematology and Oncology Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) presents significant mortality risks, underscoring the urgency of timely diagnosis and intervention. Advanced stages of CRC are managed through chemotherapy, targeted therapy, immunotherapy, radiotherapy, and surgery. Immunotherapy, while effective in bolstering the immune system against cancer cells, often carries toxic side effects, including colitis. This study aimed to evaluate the incidence of colitis in patients with metastatic CRC (mCRC) undergoing various immunotherapy treatments. Through a systematic search of Google Scholar and PubMed databases from inception until November 2023, nine relevant studies were identified. Subgroup analyses revealed a higher incidence of colitis, particularly in patients treated with anti-cytotoxic T-lymphocyte-associated molecule-4 (anti-CTLA-4) and combination therapies compared to monotherapy with programmed cell death receptor-1 (PD-1) or programmed cell death ligand receptor-1 (PDL-1) inhibitors. Notably, naive-treated metastatic CRC patients exhibited elevated colitis incidences compared to those previously treated. In conclusion, anti-CTLA-4 and combination therapies, such as nivolumab plus ipilimumab, were associated with increased colitis occurrences in metastatic CRC patients, highlighting the need for vigilant monitoring and management strategies, especially in immunotherapy-naive individuals.

Indexed as

Anti-CTLA-4anti-PD-1anti-PDL-1colitiscolorectal cancerimmunotherapyincidencemetastatic colorectal cancertoxic effects

Identifiers

PMID38910824
PMCPMC11188800

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.